

Table of Contents

Ham-Wasserman Lecture

- 1 On the architecture of translational research designed to control chronic lymphocytic leukemia
Michael Hallek

A Panoply of Immunotherapies for Adult B-Lineage Acute Lymphoblastic Leukemia

- 9 Antibody-based therapies in patients with acute lymphoblastic leukemia
Shira Dinner and Michaela Liedtke
- 16 Are CAR T cells better than antibody or HCT therapy in B-ALL?
Michael A. Pulsipher
- 25 No free rides: management of toxicities of novel immunotherapies in ALL, including financial
Tania Jain and Mark R. Litzow

Acute Myeloid Leukemia: Moving Beyond 7+3

- 35 When to obtain genomic data in acute myeloid leukemia (AML) and which mutations matter
Gregory W. Roloff and Elizabeth A. Griffiths
- 45 New drugs for acute myeloid leukemia inspired by genomics and when to use them
Daniel A. Pollyea
- 51 Cytotoxic therapy in acute myeloid leukemia: not quite dead yet
Laura C. Michaelis

Aggressive Lymphomas

- 63 Challenges and implications of genomics for T-cell lymphomas
Eric D. Jacobsen and David M. Weinstock
- 69 Genomics of aggressive B-cell lymphoma
Allison Rosenthal and Lisa Rimsza
- 75 Novel therapies for relapsed/refractory aggressive lymphomas
Jonathon B. Cohen

Approach to the Treatment of the Older, Unfit Patient with Myeloma from Diagnosis to Relapse

- 83 Treatment approach for the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a European hematologist
Thierry Facon and Kenneth Anderson
- 88 Approach to the treatment of the older, unfit patient with myeloma from diagnosis to relapse: perspectives of a US hematologist and a geriatric hematologist
Tanya M. Wildes and Kenneth C. Anderson

Approach to the Treatment of the Young, Fit Patient with Myeloma from Diagnosis to Relapse

- 97 Treatment approach for young, fit, newly diagnosed multiple myeloma patients
Saad Z. Usmani and Eric Seifter
- 103 Case-based roundtable on treatment approach for young, fit, newly diagnosed multiple myeloma patients
Sergio Giralt and Eric Seifter

As if Myeloproliferative Neoplasms Weren't Already Challenging Enough

- 110 JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy
Michele Ciboddo and Ann Mullally
- 118 Managing myelofibrosis (MF) that “blasts” through: advancements in the treatment of relapsed/refractory and blast-phase MF
Robyn M. Scherber and Ruben A. Mesa
- 127 The new tool “KIT” in advanced systemic mastocytosis
William Shomali and Jason Gotlib

AYA: Big Children or Small Adults? Leukemia Treatment in Adolescence

- 137 Genetics and prognosis of ALL in children vs adults
Kathryn G. Roberts
- 146 Long-term complications in adolescent and young adult leukemia survivors
K. Scott Baker and Karen L. Syrjala
- 154 Adolescent angst: enrollment on clinical trials
Theresa H. M. Keegan and Helen M. Parsons

Chronic Myeloid Leukemia: With Great Success Comes Great Responsibility

- 161 The argument for using imatinib in CML
Simone Claudiani and Jane F. Apperley
- 168 Molecular monitoring in CML: how deep? How often? How should it influence therapy?
Naranie Shanmuganathan and Timothy P. Hughes
- 177 We do still transplant CML, don't we?
Charles F. Craddock

Follicular Lymphoma: Have We Made Progress?

- 185 Where to start? Upfront therapy for follicular lymphoma in 2018
John P. Leonard, Loretta J. Nastoupil, and Christopher R. Flowers
- 189 Sequencing of therapies in relapsed follicular lymphoma
Loretta J. Nastoupil, Christopher R. Flowers, and John P. Leonard
- 194 Novel immunotherapy approaches to follicular lymphoma
Christopher R. Flowers, John P. Leonard, and Loretta J. Nastoupil

Hodgkin Lymphoma: Beyond ABVD for Everyone

- 200 Risk-adapted therapy for advanced-stage Hodgkin lymphoma
Michael A. Spinner and Ranjana H. Advani
- 207 Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy
Alison J. Moskowitz
- 213 Where does PD-1 blockade fit in HL therapy?
Alex F. Herrera

Reining in Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

- 221 GVHD: biology matters
James L. M. Ferrara and Mohammed S. Chaudhry
- 228 Current approaches to prevent and treat GVHD after allogeneic stem cell transplantation
Betty Ky Hamilton
- 236 Biology-driven developments in the therapy of acute graft-versus-host disease
Robert Zeiser

The Future of CLL Therapy

- 242 Selecting Frontline Therapy for CLL in 2018
Nitin Jain
- 248 Relapsed CLL: sequencing, combinations, and novel agents
Jennifer R. Brown
- 256 Richter transformation in the era of novel agents
Wei Ding

The Molecular Maelstrom of Myelodysplastic Syndromes

- 264 Clinical consequences of clonal hematopoiesis of indeterminate potential
David P. Steensma
- 270 The MDS genomics-prognosis symbiosis
Aziz Nazha
- 277 Treatments targeting MDS genetics: a fool's errand?
Amy E. DeZern

Using Genomics to Risk Stratify and Treat Kids

- 286 Using genomics to define pediatric blood cancers and inform practice
Rachel E. Rau and Mignon L. Loh
- 301 Ethical conundrums in pediatric genomics
Seth J. Rotz and Eric Kodish
- 307 JMML genomics and decisions
Charlotte M. Niemeyer

Anxiety-Provoking Consults: Macrophage Activation Syndrome, Castleman Disease, and Hypereosinophilia

- 313 The rheumatology/hematology interface: CAPS and MAS diagnosis and management
John M. Gansner and Nancy Berliner
- 318 Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease
David C. Fajgenbaum
- 326 Hypereosinophilic syndrome: approach to treatment in the era of precision medicine
Amy Klion

Delivering High-Quality Oral Anticoagulant Therapy: State of the Art in 2018

- 332 Optimizing quality care for the oral vitamin K antagonists (VKAs)
Vittorio Pengo and Gentian Denas
- 339 Drug-drug interactions in an era of multiple anticoagulants: a focus on clinically relevant drug interactions
Sara R. Vazquez
- 348 Role of the anticoagulant monitoring service in 2018: beyond warfarin
Nathan P. Clark

Thalassemia Syndromes: Diagnosis and Management in a Changing World

- 353 Potential new approaches to the management of the Hb Bart's hydrops fetalis syndrome: the most severe form of α -thalassemia
Andrew J. King and Douglas R. Higgs
- 361 Beyond transfusion therapy: new therapies in thalassemia including drugs, alternate donor transplant, and gene therapy
John Porter

Hemolytic Anemia: A Cornucopia of Causes

- 371 Complement-driven anemia: more than just paroxysmal nocturnal hemoglobinuria
Samuel A. Merrill and Robert A. Brodsky
- 377 Inherited hemolytic anemia: a possessive beginner's guide
Narla Mohandas
- 382 Autoimmune hemolytic anemia
Anita Hill and Quentin A. Hill

Hemostatic and Thromboembolic Challenges in the Young

- 390 Evaluation and management of heavy menstrual bleeding in adolescents: the role of the hematologist
Sarah H. O'Brien
- 399 Management of thrombosis in children and neonates: practical use of anticoagulants in children
Paul Monagle and Fiona Newall
- 405 Pediatric ITP: is it different from adult ITP?
Jenny M. Despotovic and Amanda B. Grimes

High-Performance Hematology: Elite Athletes and Weekend Warriors

- 412 Elite athletes and anticoagulant therapy: an intermittent dosing strategy
Stephan Moll, Joshua N. Berkowitz, and Christopher W. Miars
- 418 Balancing exercise risk and benefits: lessons learned from sickle cell trait and sickle cell anemia
Robert I. Liem

Long-Term Management of VTE: The First 6 Months and Beyond

- 426 Who should get long-term anticoagulant therapy for venous thromboembolism and with what?
Marc Alan Rodger and Gregoire Le Gal
- 432 Breadth of complications of long-term oral anticoagulant care
Walter Ageno and Marco Donadini
- 439 Anticoagulating patients with high-risk acquired thrombophilias
Leslie Skeith

Severe Aplastic Anemia: Diagnosis and Management in an Era of Effective Therapies

- 450 Activity of eltrombopag in severe aplastic anemia
Phillip Scheinberg
- 457 A brief, but comprehensive, guide to clonal evolution in aplastic anemia
Daria V. Babushok
- 467 Alternative donor transplants for severe aplastic anemia
Andrea Bacigalupo

Sickle Cell Disease: New Frontiers

- 474 The current state of sickle cell trait: implications for reproductive and genetic counseling
Lydia H. Pecker and Rakhi P. Naik
- 482 Measuring success: utility of biomarkers in sickle cell disease clinical trials and care
Ram Kalpathi and Enrico M. Novelli
- 493 New insights into the pathophysiology and development of novel therapies for sickle cell disease
Scott Moerdler and Deepa Manwani

The Interface Between “Man and Machine”: Managing Hemostasis and Thrombosis in the Plastic and Metal Circulation

- 507 Adult and pediatric mechanical circulation: a guide for the hematologist
Lisa Baumann Kreuziger and M. Patricia Massicotte
- 516 An introduction to point-of-care testing in extracorporeal circulation and LVADs
Rachel Sara Bercovitz
- 522 Preventing and managing catastrophic bleeding during extracorporeal circulation
Keyvan Karkouti and Loretta T. S. Ho

TTP 2019: State of the Art

- 530 Clinical and laboratory diagnosis of TTP: an integrated approach
Thita Chiasakul and Adam Cuker
- 539 Beyond plasma exchange: novel therapies for thrombotic thrombocytopenic purpura
Kathryn Dane and Shruti Chaturvedi
- 548 TTP: long-term outcomes following recovery
James N. George

Update in Transfusion Therapy for Hematological Malignancies: Transfusion Support—TACO and TRALI

- 553 Shifting ground and gaps in transfusion support of patients with hematological malignancies
Christine Cserti-Gazdewich
- 585 TACO and TRALI: biology, risk factors, and prevention strategies
Nareg Roubinian

What's Hot in ITP

- 561 How do we diagnose immune thrombocytopenia in 2018?
John G. Kelton, John R. Vrbensky, and Donald M. Arnold
- 568 Evidence-based management of immune thrombocytopenia: ASH guideline update
Cindy E. Neunert and Nichola Cooper
- 576 Drug-associated thrombocytopenia
Tamam Bakchoul and Irene Marini

Erratum

- 584 Neunert CE. Management of newly diagnosed immune thrombocytopenia: can we change outcomes?
Hematology Am Soc Hematol Educ Program. 2017;2017:400-405.